Furthermore, the expression of TRIM3 correlated with poorer OS, RFS, and DMFS in patients with ER+ breast cancer upon tamoxifen treatment, but not in patients with ER− breast cancer (Figs. 1C and S1C), suggesting that TRIM3 might be a potential predictive marker for the response to tamoxifen in patients with ER+ breast cancer. Here, ESR1 is linked to breast cancer.